Risk of premature menopause in women treated for Hodgkin lymphoma according to chemotherapy regimen, compared with women who were treated with radiotherapy only, provided the ovaries were not located in the radiation fields
| . | Patients, no.* . | % . | Events, no. . | Py . | Events/1000 Py . | HR (95% CI) . | P-trend† . |
|---|---|---|---|---|---|---|---|
| RT alone | 245 | 47 | 6 | 2426 | 2 | 1 (ref) | — |
| CT, yes/no‡ | 331 | 64 | 91 | 2760 | 33 | 12.3 (5.3-28.8) | — |
| MOPP§ | 141 | 28 | 56 | 1001 | 56 | 5.7 (3.6-9.1) | — |
| 1 to 3 cycles of MOPP | 37 | 7 | 24 | 297 | 37 | 3.8 (1.8-7.8) | — |
| 4 to 6 cycles of MOPP | 68 | 13 | 21 | 535 | 45 | 4.4 (2.5-8.0) | — |
| More than 6 cycles of MOPP | 39 | 8 | 3 | 169 | 124 | 11.6 (6.5-20.7) | .001 |
| MOPP/ABV§ | 85 | 17 | 16 | 642 | 25 | 2.9 (1.6-5.2) | — |
| 1 to 6 cycles of MOPP/ABV | 69 | 14 | 11 | 507 | 22 | 2.6 (1.3-5.2) | — |
| More than 6 cycles of MOPP/ABV | 18 | 4 | 5 | 135 | 37 | 4.8 (1.8-12.8) | .01 |
| ABVD§ | 25 | 5 | 1 | 260 | 4 | 0.3 (0.0-1.9) | — |
| EBVP§ | 25 | 5 | 5 | 217 | 23 | 1.2 (0.5-3.3) | — |
| . | Patients, no.* . | % . | Events, no. . | Py . | Events/1000 Py . | HR (95% CI) . | P-trend† . |
|---|---|---|---|---|---|---|---|
| RT alone | 245 | 47 | 6 | 2426 | 2 | 1 (ref) | — |
| CT, yes/no‡ | 331 | 64 | 91 | 2760 | 33 | 12.3 (5.3-28.8) | — |
| MOPP§ | 141 | 28 | 56 | 1001 | 56 | 5.7 (3.6-9.1) | — |
| 1 to 3 cycles of MOPP | 37 | 7 | 24 | 297 | 37 | 3.8 (1.8-7.8) | — |
| 4 to 6 cycles of MOPP | 68 | 13 | 21 | 535 | 45 | 4.4 (2.5-8.0) | — |
| More than 6 cycles of MOPP | 39 | 8 | 3 | 169 | 124 | 11.6 (6.5-20.7) | .001 |
| MOPP/ABV§ | 85 | 17 | 16 | 642 | 25 | 2.9 (1.6-5.2) | — |
| 1 to 6 cycles of MOPP/ABV | 69 | 14 | 11 | 507 | 22 | 2.6 (1.3-5.2) | — |
| More than 6 cycles of MOPP/ABV | 18 | 4 | 5 | 135 | 37 | 4.8 (1.8-12.8) | .01 |
| ABVD§ | 25 | 5 | 1 | 260 | 4 | 0.3 (0.0-1.9) | — |
| EBVP§ | 25 | 5 | 5 | 217 | 23 | 1.2 (0.5-3.3) | — |
Py indicates person-years; and —, not applicable.
Ten patients with missing information on number of cycles of MOPP or MOPP/ABV were excluded; patients may contribute person-time to more than one category.
Based on the slope of continuous number of cycles of a given regimen among those treated with that regimen.
Adjusted for smoking, oral contraceptive use, dose level of radiotherapy, and age at first treatment; age was used as the time scale.
Adjusted for smoking, oral contraceptive use, dose level of radiotherapy, age at first treatment, each other, and other chemotherapy (alkylating chemotherapy only: yes/no, nonalkylating chemotherapy only: yes/no, alkylating and nonalkylating chemotherapy: yes/no, unknown chemotherapy regimen: yes/no); age was used as the time scale.